MetaCap

Septerna (SEPN) vs Vera Therapeutics (VERA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Septerna (SEPN) has outperformed Vera Therapeutics (VERA) over the past year, gaining 51.1% versus a loss of 10.6%. Vera Therapeutics is the larger company by market cap ($1.84 billion vs $1.84 billion), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

SEPN+51.06%VERA-10.58%
+111%+47%-16%
Nov 21, 20251 yearNov 20, 2026
SEPN+80.42%VERA-38.06%
+138%+27%-85%
Oct 21, 20245 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

SEPN versus VERA key metrics
MetricSEPNVERA
Share price$38.61$25.45
Market cap$1.84B$1.84B
1-day change-1.51%-4.86%
YTD return+38.49%-49.74%
1-year return+51.06%-10.58%
5-year return—-15.17%
EPS (TTM)$-1.30$-5.90
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$45.95M—
Revenue growth (YoY)+4174.51%—
Net income (latest FY)$-48.88M$-299.62M
Operating margin-148.63%—
Net margin-106.37%—
52-week high$53.34$56.05
52-week low$22.78$25.08
Distance from 52-week high-27.62%-54.59%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+53.38%+180.39%
Average volume383.96K1.95M
Shares outstanding47.55M72.30M
Employees134362
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • SEPN has outperformed VERA by 61.6 percentage points over the past year.

About Septerna

SEPN stock →

Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; and TSHR Program, an oral small molecule TSHR NAM for graves' disease and thyroid eye disease.

Health Care · Biotechnology: Pharmaceutical Preparations · 134 employees

About Vera Therapeutics

VERA stock →

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases. The company offers atacicept, a fully humanized TACI-Fc fusion protein that binds B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), which is self-administered at home as a subcutaneous injection being evaluated for the treatment of immunoglobulin A nephropathy (IgAN) and other autoimmune kidney diseases.

Health Care · Biotechnology: Pharmaceutical Preparations · 362 employees

SEPN vs VERA FAQ

Which is bigger, Septerna or Vera Therapeutics?

Vera Therapeutics (VERA) is larger, with a market capitalization of $1.84B compared with $1.84B for Septerna (SEPN).

Which stock has performed better over the past year, SEPN or VERA?

SEPN returned +51.06% over the past 12 months, compared with -10.58% for VERA (price return, excluding dividends). Past performance does not predict future results.

Are Septerna and Vera Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons